Streptomycin

EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS

Streptomycin

---

CLASS

Aminoglycoside

---

TARGET PROTEIN

hinders formyl-methionyl-tRNA to bind with bacterial ribosomal 30S subunit

---

MECHANISM OF ACTION

Bactericidal effect or Bacteriostatic (It is a protein synthesis inhibitor that hinders binding of formyl-methionyl-tRNA to the bacterial ribosomal 30S subunit)

---

DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)

Approved

---

MODE OF ADMINISTRATION

Injectable

---

LINK TO PUBMED

https://pubmed.ncbi.nlm.nih.gov/32091697/

https://pubmed.ncbi.nlm.nih.gov/30136733/

---

SIMILAR TARGETS IN OTHER SPECIES

Ribosomal RNA ~ Enteric bacteria and other eubacteria

---

DRUG BANK ID

DB01082

---

EXTERNAL LINKS

Human Metabolome Database HMDB0015214

KEGG Compound C00413

PubChem Compound 19649

PubChem Substance 46506845

ChemSpider 18508

BindingDB 50103513

RxNav 10109

ChEBI 17076

ChEMBL CHEMBL372795

ZINC ZINC000008214681

Drugs.com Drugs.com Drug Page  https://www.drugs.com/cdi/streptomycin.html

Wikipedia Streptomycin

---

REFERENCE

Yotsu, R. R., Richardson, M., & Ishii, N. (2018). Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). Cochrane Database of Systematic Reviews, 2018(8). https://doi.org/10.1002/14651858.CD012118.pub2



Pluschke, G., & Röltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4

---